Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Czech | Norway | Pakistan
Approved Indications: None
Known Adverse Events: None
Company: Johns Hopkins Bloomberg School of Public Health
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Taeniasis|Neurocysticercosis
Phase 2: Trichuriasis|Communicable Diseases|Fascioliasis
Phase 1: Neurocysticercosis|Filariasis|Taeniasis|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04920292 |
HELP-OFZ | P1 |
Completed |
Filariasis |
2022-11-07 |
2022-12-07 |
Primary Completion Date|Primary Endpoints|Start Date |
|
NCT03035760 |
HHSN272201300020I | P1 |
Completed |
Healthy Volunteers |
2018-04-23 |
2019-12-18 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT01584362 |
OXFEND-02 | P1 |
Withdrawn |
Neurocysticercosis |
2016-08-01 |
2019-03-19 |
Treatments |
|
NCT02234570 |
NCT02234570 | P1 |
Completed |
Neurocysticercosis|Taeniasis |
2015-11-24 |
2024-06-26 |
Primary Endpoints |
|
NCT06367361 |
SIDISI 201221 | P2 |
Not yet recruiting |
Fascioliasis |
2028-03-01 |
2024-08-16 |
Primary Endpoints|Treatments |
|
NCT03435718 |
OXF2 v3.21 | P2 |
Not yet recruiting |
Trichuriasis|Communicable Diseases |
2026-07-01 |
2023-11-09 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
|
NCT04713787 |
IND158335 | P2 |
Recruiting |
Trichuriasis |
2026-01-30 |
2025-04-16 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT02636803 |
OXF2 | P2 |
Withdrawn |
Trichuriasis |
2020-08-01 |
2019-08-21 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06565507 |
NCT06565507 | P3 |
Not yet recruiting |
Neurocysticercosis|Taeniasis |
2028-03-30 |
2024-08-23 |
Primary Endpoints|Treatments |